$220 Million is the total value of EcoR1 Capital, LLC's 25 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 64.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FGEN | Buy | FIBROGEN INC | $26,970,000 | -4.8% | 1,230,391 | +2.1% | 12.28% | +30.0% |
| ATRA | Sell | ATARA BIOTHERAPEUTICS INC | $25,261,000 | -55.0% | 803,458 | -24.4% | 11.50% | -38.5% |
| Buy | ARRAY BIOPHARMA INCnote | $22,210,000 | -8.4% | 22,534,000 | +17.4% | 10.11% | +25.1% | |
| RTRX | Buy | RETROPHIN INC | $20,415,000 | +80.2% | 1,007,660 | +194.9% | 9.29% | +146.1% |
| EPZM | Sell | EPIZYME INC | $19,196,000 | -52.6% | 1,492,700 | -11.5% | 8.74% | -35.2% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $18,040,000 | -40.5% | 1,887,069 | +19.9% | 8.21% | -18.8% |
| KITE | KITE PHARMA INC | $15,668,000 | -8.7% | 281,400 | 0.0% | 7.13% | +24.7% | |
| FLKS | Buy | FLEX PHARMA INC | $11,214,000 | -28.2% | 933,691 | +2.8% | 5.10% | -2.1% |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $10,284,000 | +23.9% | 465,118 | 0.0% | 4.68% | +69.2% | |
| LIFE | Buy | ATYR PHARMA INC | $8,623,000 | -44.4% | 840,462 | +0.4% | 3.92% | -24.0% |
| NBRV | New | NABRIVA THERAPEUTICS AGsponsored adr | $7,938,000 | – | 835,530 | +100.0% | 3.61% | – |
| KIN | Buy | KINDRED BIOSCIENCES INC | $6,882,000 | -22.0% | 1,323,431 | +2.2% | 3.13% | +6.4% |
| GNVC | GENVEC INC | $4,589,000 | +13.3% | 1,986,413 | 0.0% | 2.09% | +54.6% | |
| CLDN | CELLADON CORP | $2,985,000 | -16.7% | 2,843,170 | 0.0% | 1.36% | +13.8% | |
| ONTY | New | ONCOTHYREON INC | $2,585,000 | – | 943,500 | +100.0% | 1.18% | – |
| AKTX | New | AKARI THERAPEUTICS PLCsponsored adr | $2,417,000 | – | 100,709 | +100.0% | 1.10% | – |
| FWP | Sell | FORWARD PHARMA A/Ssponsored adr | $2,403,000 | -60.3% | 101,995 | -35.8% | 1.09% | -45.8% |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $2,293,000 | – | 149,000 | +100.0% | 1.04% | – |
| CALA | CALITHERA BIOSCIENCES INC | $2,256,000 | -24.0% | 415,480 | 0.0% | 1.03% | +3.8% | |
| New | GILEAD SCIENCES INCcall | $2,148,000 | – | 3,255 | +100.0% | 0.98% | – | |
| OREX | New | OREXIGEN THERAPEUTICS INC | $1,979,000 | – | 937,958 | +100.0% | 0.90% | – |
| QLTI | Buy | QLT INC | $1,699,000 | +2.8% | 638,900 | +59.7% | 0.77% | +40.3% |
| New | VALEANT PHARMACEUTICALS INTLcall | $1,347,000 | – | 1,265 | +100.0% | 0.61% | – | |
| CBIO | New | CATALYST BIOSCIENCES INC | $261,000 | – | 56,000 | +100.0% | 0.12% | – |
| REGULUS THERAPEUTICS INCcall | $35,000 | -97.5% | 1,280 | 0.0% | 0.02% | -96.6% | ||
| Exit | EPIZYMEcall | $0 | – | -150 | -100.0% | -0.12% | – | |
| XENE | Exit | XENON PHARMACEUTICALS | $0 | – | -73,000 | -100.0% | -0.28% | – |
| MCRB | Exit | SERES THERAPEUTICS | $0 | – | -40,000 | -100.0% | -0.55% | – |
| TRGT | Exit | TARGACEPT | $0 | – | -619,699 | -100.0% | -0.58% | – |
| BITI | Exit | BIOTIE THERAPIES OYJ SPONSORED ADRsponsored adr | $0 | – | -100,000 | -100.0% | -0.67% | – |
| ARRY | Exit | ARRAY BIOPHARMA | $0 | – | -400,000 | -100.0% | -0.96% | – |
| Exit | OVASCIENCEcall | $0 | – | -2,300 | -100.0% | -2.22% | – | |
| Exit | ARRAY BIOPHARMAcall | $0 | – | -11,000 | -100.0% | -2.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.